RhumbLine Advisers
FBIO icon

RhumbLine Advisers’s Fortress Biotech FBIO Stock Holding History

RhumbLine Advisers’s Portfolio FBIO Stock Details FBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-4,607
Closed -$94K – 3143
2022
Q1 		$94K Buy
4,607
+586
+15% +$16K ﹤0.01% 2897
2021
Q4 		$151K Sell
4,021
-20
-0.5% -$892 ﹤0.01% 2886
2021
Q3 		$195K Buy
4,041
+164
+4% +$8.01K ﹤0.01% 2917
2021
Q2 		$208K Buy
3,877
+314
+9% +$18.9K ﹤0.01% 2917
2021
Q1 		$189K Buy
3,563
+32
+0.9% +$1.8K ﹤0.01% 2842
2020
Q4 		$168K Buy
3,531
+388
+12% +$16.8K ﹤0.01% 2879
2020
Q3 		$190K Sell
3,143
-225
-7% -$11.5K ﹤0.01% 2706
2020
Q2 		$135K Buy
+3,368
New +$125K ﹤0.01% 2893
2019
Q2 		– Sell
-2,953
Closed -$79K – 2979
2019
Q1 		$79K Sell
2,953
-56
-2% -$1.47K ﹤0.01% 2887
2018
Q4 		$39K Buy
3,009
+944
+46% +$15.8K ﹤0.01% 2958
2018
Q3 		$50K Sell
2,065
-129
-6% -$4.13K ﹤0.01% 2908
2018
Q2 		$98K Buy
2,194
+197
+10% +$11.1K ﹤0.01% 2873
2018
Q1 		$136K Sell
1,997
-21
-1% -$1.33K ﹤0.01% 2688
2017
Q4 		$121K Sell
2,018
-631
-24% -$37.2K ﹤0.01% 2748
2017
Q3 		$176K Buy
2,649
+59
+2% +$3.98K ﹤0.01% 2784
2017
Q2 		$185K Buy
2,590
+72
+3% +$4.25K ﹤0.01% 2785
2017
Q1 		$140K Buy
2,518
+715
+40% +$32K ﹤0.01% 2732
2016
Q4 		$73K Buy
1,803
+201
+13% +$7.51K ﹤0.01% 2812
2016
Q3 		$71K Buy
1,602
+513
+47% +$21.8K ﹤0.01% 2841
2016
Q2 		$44K Buy
+1,089
New +$50.7K ﹤0.01% 2966
2014
Q2 		– Sell
-1,268
Closed -$38K – 3023
2014
Q1 		$38K Sell
1,268
-72
-5% -$2.81K ﹤0.01% 2967
2013
Q4 		$53K Hold
1,340
– – ﹤0.01% 2997
2013
Q3 		$141K Sell
1,340
-6
-0.4% -$736 ﹤0.01% 2883
2013
Q2 		$174K Buy
+1,346
New +$198K ﹤0.01% 3048

Other funds holding FBIO

NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
OMC
Oasis Management Company Grand Cayman, Cayman Islands $1.88B AUM 54.21% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
SAM
Shikiar Asset Management New York $396M AUM 41.06% 1-Year Est. Return
CL
CPWM LLC Seattle, Washington $1.06B AUM 14.49% 1-Year Est. Return
PCM
Perkins Capital Management Wayzata, Minnesota $133M AUM 127.86% 1-Year Est. Return

RhumbLine Advisers's FBIO Position: Q2 2022 in Review

RhumbLine Advisers sold out of Fortress Biotech (FBIO) in Q2 2022, closing a stake of 4,607 shares — an estimated $94K sold.

RhumbLine Advisers first reported a position in FBIO in Q2 2013 and held it in 24 quarters. The position peaked at $208K in Q2 2021. 66 funds tracked by Wall St. Rank hold FBIO as of Q2 2022.

  • RhumbLine Advisers reported no remaining Fortress Biotech position as of Q2 2022 after selling out during the quarter.
  • RhumbLine Advisers sold 4,607 Fortress Biotech shares in Q2 2022, an estimated $94K.
  • RhumbLine Advisers first reported a position in Fortress Biotech in Q2 2013 and held it in 24 quarters.
  • RhumbLine Advisers's Fortress Biotech position peaked at $208K in Q2 2021.
  • 66 funds tracked by Wall St. Rank held Fortress Biotech as of Q2 2022.

Based on RhumbLine Advisers's 13F filing for Q2 2022, filed 11 Aug 2022.